contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


zealand-pharma-major-shareholder-announcement-polar-capital

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Zealand Pharma är verksamt inom bioteknik. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg, Danmark.

Zealand Pharma

Company announcement – No. 47 / 2022 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark and Boston, MA, 11 October 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq...

Company announcement – No. 47 / 2022 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark and Boston, MA, 11 October 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 11 October 2022 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As of 10 October 2022, Polar Capital LLP holds nominally 5,930,317 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 11.51% of the total share capital and total voting rights in Zealand Pharma A/S. Please see further details in the attached notification form. # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=r1jJLtmoiU6kjJHRNjTmdScEh2WUtuIDSUVvj8FjM3A2dEGKgKAvkxN_UF3RMjBEbHsmQ7uAZdnYf90gWfWuFc2DGJoWNBTR4eBJN7b6BWKOoo851rw7e-L1pIHvtzzsqA6Txk9hfZH_AG68cn7hS-mxSDcyr2woirxw0sRJivkj011xJhii3S8FU_byulFnn_fcnLV5a8RWavKJJIqxEBqzoEv3aqADsV-Q1NyHKCftUE6bWQZ-xszkZYoy1RjXS-dve0giDtmKIXbSxO4q8g==">www.zealandpharma.com</a>. Contact: <table style="border-collapse: collapse; border-collapse:collapse ;"><tbody><tr><td> Anna Krassowska, PhD Vice President, Investor Relations &amp; Corporate Communications Zealand Pharma Email: <a href="mailto:ank@zealandpharma.com">ank@zealandpharma.com</a> &nbsp; David Rosen (U.S. Media) Argot Partners Email: <a href="mailto:media@zealandpharma.com">media@zealandpharma.com</a> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; </td></tr></tbody></table> Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/a34baf8d-24df-4a53-8f4d-1d57ac5a4864">Zealand Pharma - Disclosure Form - 11.10.2022</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDc1MDI3OCM0MDEzOTk4NDAjMjAwMTcwMQ=="> <img src="https://ml-eu.globenewswire.com/media/ZDA1Mzk5OTctNzUyOC00OWVmLTk5YjAtNWU4ZWJlOTE2MmEzLTEwMTMyNzQ=/tiny/Zealand-Pharma.png">